Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $880.00 by Analysts at HSBC

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective reduced by analysts at HSBC from $990.00 to $880.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HSBC’s price target suggests a potential upside of 35.21% from the company’s previous close.

A number of other research firms have also recently issued reports on REGN. Truist Financial decreased their target price on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. Leerink Partners reissued a “market perform” rating and set a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a report on Monday, May 18th. Finally, JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $817.65.

Regeneron Pharmaceuticals Stock Down 0.5%

Shares of REGN stock traded down $3.45 during trading on Monday, reaching $650.82. The company’s stock had a trading volume of 370,572 shares, compared to its average volume of 869,657. The business has a fifty day moving average price of $652.48 and a 200-day moving average price of $725.31. Regeneron Pharmaceuticals has a one year low of $532.60 and a one year high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The company has a market cap of $68.80 billion, a price-to-earnings ratio of 15.84, a price-to-earnings-growth ratio of 1.44 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The firm’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same period in the previous year, the company earned $8.22 earnings per share. Analysts anticipate that Regeneron Pharmaceuticals will post 37.44 earnings per share for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. WPG Advisers LLC increased its stake in Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the period. Western Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $26,000. SHP Wealth Management purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $26,000. Titan Wealth CI Ltd purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $29,000. Finally, Board of the Pension Protection Fund bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at about $31,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.